Our results demonstrated that PI3K inhibitors showed prominently therapeutic efficacy in PIK3CA-altered HPVneg HNSCC while CDK4/6 inhibition has also been proven to improve the response to PI3K inhibitors in PIK3CA-mutated breast cancers [62]. The gene discussed is PIK3CA; the disease is breast carcinoma.